Brief: NeuroPace, Inc. Q2 EPS USD -0.26

NeuroPace

12/08/2025 21:05

Overview

NeuroPace Inc Q2 revenue grows 22% yr/yr to $23.5 mln, beating estimates

Company raises full-year 2025 revenue guidance to $94-$98 mln

Gross margin improves to 77.1% driven by manufacturing efficiencies

Outlook

NeuroPace raises 2025 revenue guidance to $94 mln-$98 mln

Company increases 2025 gross margin guidance to 75%-76%

Result Drivers

RNS SYSTEM SALES - Revenue growth driven by increased sales of the RNS System

MANUFACTURING EFFICIENCIES - Strong gross margin of 77.1% attributed to manufacturing efficiencies and positive product mix

PROJECT CARE MOMENTUM - Increased contribution from Project CARE in Q2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$23.52 mln
$23.10 mln (8 Analysts)
Q2 EPS
-$0.26
Q2 Net Income
-$8.65 mln
Q2 Gross Profit
$18.13 mln
Q2 Income from Operations
-$6.82 mln
Q2 Operating Expenses
$24.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuropace Inc is $17.00, about 47.7% above its August 11 closing price of $8.89

Press Release: ID:nGNX1fD17D

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)